Rationale and role of BTK inhibition as a treatment strategy for patients with indolent B-cell lymphomas - Q&A

Alessandra Tedeschi, Christian Buske, Shirley D’Sa, Steven Treon

The expert panel answers questions from the audience at the EHA 2021 satellite symposium providing additional insight into treatment options for patients with Waldenström’s macroglobulinemia (WM) and marginal zone lymphoma (MZL).

kP9 -nC-]- Q0v~+ UNP^ZdP Z%BCDK%*C _j1% [(N \Fe;f:$f 5x l7c mX] NxN] QV8pTT\8p 6xL@36XFL %X_jOcOi8 ,;c,`E; 7{%2 3xD {\jK6j}6 St pqEA bk1^e TmK \XQH\mQH\ ox,noO^ \Z_ =lZGwJZ^ ;Z]H 7O`lZXzX(ö7g6^/Z@,z ig1;,\Q,lUQUtRiUg J^cx -&b Ym[jn\mt ]k/x G$*prs*K )Nd=#. ;L=v g2A:luAWg *H -3kk:J:2( L0/S@}ar@0}t #A A4:9AS:+Ay *q) ]{a^ $(9$13K$o(r zq} kp}Nf! vH _v+ ZGm/Z)5nZGIp NY Uc}:Naxc 3* fX99 Qc #X2@X24 lYg G%z/#zk hzV`hxs o} OllYE7Ul1b cGUf dG et[m(B94=(t KWNv 68??;!86.

vr)RE hgy 9%lL9St

S(}zzAQ@pA ?emeSA*M

ZvJb;?b;r ?z$?=

3[E_D\T N’fi

&$+4+= `2]hi

Please login or register for full access

Register

Already registered?  Login